AstraZeneca Rues Loss Of Drug Exclusivity
Patent expiry continues to haunt AstraZeneca, Britain's second-largest drugmaker, which reported a 19% slide in third-quarter sales on Thursday.
The company said it was hurt by the loss of exclusivity for Seroquel IR, its bestselling antipsychotic treatment, as well as Atacand for high blood pressure, antibiotic Merrem, cholesterol drug Crestor in Canada and heartburn pill Nexium in Europe. Revenues fell to $6.7bn (£4.15bn) in the third quarter from $8.2bn a year ago.
New boss Pascal Soriot, who joined from Roche and suspended share buybacks on his first day in the job at the beginning of the month, said buying in new treatments would be an important way of rebuilding the pipeline. He added that the recently launched heart drug Brilinta had the potential to do far better.
Continue reading Guardian coverage here.
Thank You Guardian.uk and Ms Kollowe
The IR suffix stands for Immediate Release as opposed to the XR which stands for Extended Release.
Use the following search tool to view a summary of adverse reactions experienced by patients taking psychiatric drugs, culled from Individual Safety Reports (ISRs) submitted to the FDA's Adverse Event Reporting System (MedWatch) between January of 2004 and September of 2009.
| Quetiapine | Reported By | ||||||
| Adverse Reaction | Cases | MD | CN | OT | PH | LW | NR |
| Suicidal Ideations | 479 | 103 | 106 | 72 | 13 | 7 | 266 |
| Attempted Suicides | 325 | 142 | 33 | 86 | 15 | 7 | 142 |
| Completed Suicides | 300 | 105 | 21 | 146 | 57 | 1 | 39 |
| Deaths Not From Suicide | 1,274 | 450 | 95 | 312 | 38 | 346 | 869 |
| Homicidal Ideations | 31 | 6 | 2 | 7 | 1 | 0 | 19 |
| Homicides | 16 | 0 | 6 | 2 | 0 | 0 | 9 |
| Hypomania/Mania | 123 | 40 | 26 | 24 | 5 | 0 | 40 |
| Heart Disease | 473 | 151 | 42 | 98 | 23 | 9 | 303 |
| Movement Disorders | 1,561 | 614 | 258 | 381 | 82 | 13 | 508 |
| Birth Defects | 39 | 19 | 3 | 12 | 2 | 0 | 16 |
| Premature Births | 11 | 4 | 0 | 8 | 1 | 0 | 2 |
| Prenatal/Neonatal Deaths | 38 | 19 | 5 | 18 | 1 | 0 | 10 |
No comments:
Post a Comment